Optimizing NK-92 serial killers: gamma irradiation, CD95/Fas-ligation, and NK or LAK attack limit cytotoxic efficacy
- PMID: 35366943
- PMCID: PMC8976335
- DOI: 10.1186/s12967-022-03350-6
Optimizing NK-92 serial killers: gamma irradiation, CD95/Fas-ligation, and NK or LAK attack limit cytotoxic efficacy
Abstract
Background: The NK cell line NK-92 and its genetically modified variants are receiving attention as immunotherapies to treat a range of malignancies. However, since NK-92 cells are themselves tumors, they require irradiation prior to transfer and are potentially susceptible to attack by patients' immune systems. Here, we investigated NK-92 cell-mediated serial killing for the effects of gamma-irradiation and ligation of the death receptor Fas (CD95), and NK-92 cell susceptibility to attack by activated primary blood NK cells.
Methods: To evaluate serial killing, we used 51Cr-release assays with low NK-92 effector cell to target Raji, Daudi or K562 tumor cell (E:T) ratios to determine killing frequencies at 2-, 4-, 6-, and 8-h.
Results: NK-92 cells were able to kill up to 14 Raji cells per NK-92 cell in 8 h. NK-92 cells retained high cytotoxic activity immediately after irradiation with 10 Gy but the cells surviving irradiation lost > 50% activity 1 day after irradiation. Despite high expression of CD95, NK-92 cells maintained their viability following overnight Fas/CD95-ligation but lost some cytotoxic activity. However, 1 day after irradiation, NK-92 cells were more susceptible to Fas ligation, resulting in decreased cytotoxic activity of the cells surviving irradiation. Irradiated NK-92 cells were also susceptible to killing by both unstimulated and IL-2 activated primary NK cells (LAK). In contrast, non-irradiated NK-92 cells were more resistant to attack by NK and LAK cells.
Conclusions: Irradiation is deleterious to both the survival and cytotoxicity mediated by NK-92 cells and renders the NK-92 cells susceptible to Fas-initiated death and death initiated by primary blood NK cells. Therefore, replacement of irradiation as an antiproliferative pretreatment and genetic deletion of Fas and/or NK activation ligands from adoptively transferred cell lines are indicated as new approaches to increase therapeutic efficacy.
Keywords: Adoptive cell transfer; Fas/CD95; Limitations; Lymphokine activated killer; NK; NK-92; Radiation; Serial killing; Therapeutic efficacy.
© 2022. The Author(s).
Conflict of interest statement
Not applicable.
Figures





Similar articles
-
Target cell-induced apoptosis of interleukin-2-activated human natural killer cells: roles of cell surface molecules and intracellular events.Blood. 1996 Jun 15;87(12):5127-35. Blood. 1996. PMID: 8652825
-
Relation of natural killer cell line NK-92-mediated cytolysis (NK-92-lysis) with the surface markers of major histocompatibility complex class I antigens, adhesion molecules, and Fas of target cells.Oncol Res. 1998;10(10):483-9. Oncol Res. 1998. PMID: 10338151
-
Radiation sensitivity of resting and activated nonspecific cytotoxic cells of T lineage and NK lineage.Blood. 1989 May 1;73(6):1615-21. Blood. 1989. PMID: 2785411
-
New mechanism of organophosphorus pesticide-induced immunotoxicity.J Nippon Med Sch. 2007 Apr;74(2):92-105. doi: 10.1272/jnms.74.92. J Nippon Med Sch. 2007. PMID: 17507786 Review.
-
The mechanism of organophosphorus pesticide-induced inhibition of cytolytic activity of killer cells.Cell Mol Immunol. 2006 Jun;3(3):171-8. Cell Mol Immunol. 2006. PMID: 16893497 Review.
Cited by
-
Repurposing anti-mesothelin CAR-NK immunotherapy against colorectal cancer.J Transl Med. 2024 Dec 4;22(1):1100. doi: 10.1186/s12967-024-05851-y. J Transl Med. 2024. PMID: 39627822 Free PMC article.
-
TCR-NK Cells: A Novel Source for Adoptive Immunotherapy of Cancer.Turk J Haematol. 2023 Feb 28;40(1):1-10. doi: 10.4274/tjh.galenos.2022.2022.0534. Epub 2023 Jan 31. Turk J Haematol. 2023. PMID: 36719099 Free PMC article. Review.
-
ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma.Front Immunol. 2023 Aug 18;14:1228894. doi: 10.3389/fimmu.2023.1228894. eCollection 2023. Front Immunol. 2023. PMID: 37662907 Free PMC article.
-
Curative timed NK cell-based immunochemotherapy aborts brain tumour recurrence driven by mesenchymal glioma stem cells.Acta Neuropathol Commun. 2025 Mar 21;13(1):64. doi: 10.1186/s40478-025-01984-3. Acta Neuropathol Commun. 2025. PMID: 40119461 Free PMC article.
-
iPSCs in NK Cell Manufacturing and NKEV Development.Front Immunol. 2022 Jul 8;13:890894. doi: 10.3389/fimmu.2022.890894. eCollection 2022. Front Immunol. 2022. PMID: 35874677 Free PMC article. Review.
References
-
- Miller JS, Lanier LL. Natural killer cells in cancer immunotherapy. Ann Rev Cancer Biol. 2019;3(1):77–103.
-
- Isaaz S, Baetz K, Olsen K, Podack E, Griffiths GM. Serial killing by cytotoxic T lymphocytes: T cell receptor triggers degranulation, re-filling of the lytic granules and secretion of lytic proteins via a non-granule pathway. Eur J Immunol. 1995;25(4):1071–1079. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous